Oncology and Hematology - Global Oncology Academy

561-576 of 804

First-Line Maintenance Therapy Using PARP Inhibitors for Ovarian Cancer
First-Line Maintenance Therapy Using PARP Inhibitors for Ovarian Cancer
MinuteCE®
First-Line Maintenance Therapy Using PARP Inhibitors for Ovarian Cancer
Nicoletta Colombo, MD; Ritu Salani, MD
1.00 program credit
- Nicoletta Colombo, MD
- Ritu Salani, MD
1.00 program credit
Incorporation of guideline-concordant care for first-line treatment of a patient with metastatic urothelial carcinoma
Incorporation of guideline-concordant care for first-line treatment of a patient with metastatic urothelial carcinoma
MinuteCE®
Incorporation of guideline-concordant care for first-line treatment of a patient with metastatic urothelial carcinoma
Ignacio Duran, MD; Sandy Srinivas, MD
1.25 program credits
- Ignacio Duran, MD
- Sandy Srinivas, MD
1.25 program credits
Guideline Considerations for Immunotherapy in Primary Advanced or Recurrent Endometrial Cancer
Guideline Considerations for Immunotherapy in Primary Advanced or Recurrent Endometrial Cancer
MinuteCE®
Guideline Considerations for Immunotherapy in Primary Advanced or Recurrent Endometrial Cancer
Susana Campos, MD, MPH; Ritu Salani, MD
1.00 program credit
- Susana Campos, MD, MPH
- Ritu Salani, MD
1.00 program credit
Guideline-Based, Biomarker-Directed Treatment Options in Second-Line Recurrent Endometrial Cancer
Guideline-Based, Biomarker-Directed Treatment Options in Second-Line Recurrent Endometrial Cancer
MinuteCE®
Guideline-Based, Biomarker-Directed Treatment Options in Second-Line Recurrent Endometrial Cancer
Nicoletta Colombo, MD; Susana Campos, MD, MPH
1.00 program credit
- Nicoletta Colombo, MD
- Susana Campos, MD, MPH
1.00 program credit
Guideline-recommended second-line treatment following an immune checkpoint inhibitor in renal cell carcinoma
Guideline-recommended second-line treatment following an immune checkpoint inhibitor in renal cell carcinoma
MinuteCE®
Guideline-recommended second-line treatment following an immune checkpoint inhibitor in renal cell carcinoma
Ignacio Duran, MD; Wenxin Xu, MD
1.25 program credits
- Ignacio Duran, MD
- Wenxin Xu, MD
1.25 program credits
Treating R/R Classic Hodgkin Lymphoma: Ipilimumab and Other Approaches
Treating R/R Classic Hodgkin Lymphoma: Ipilimumab and Other Approaches
Project Oncology®
Treating R/R Classic Hodgkin Lymphoma: Ipilimumab and Other Approaches
Supplements and Cannabis in Breast Cancer Care: An Integrative Medicine Approach
Supplements and Cannabis in Breast Cancer Care: An Integrative Medicine Approach
Project Oncology®
Supplements and Cannabis in Breast Cancer Care: An Integrative Medicine Approach
Heather Greenlee, ND, PhD, MPH
- Heather Greenlee, ND, PhD, MPH
The Potential Link Between COVID-19 and Cancer Regression
The Potential Link Between COVID-19 and Cancer Regression
Clinician's Roundtable
The Potential Link Between COVID-19 and Cancer Regression
Ankit Bharat, MD; Brian P. McDonough, MD, FAAFP
- Ankit Bharat, MD
- Brian P. McDonough, MD, FAAFP
Understanding iMCD Through RNA Sequencing
Understanding iMCD Through RNA Sequencing
Project Oncology®
Understanding iMCD Through RNA Sequencing
Michael Gonzalez, PhD, MSc
- Michael Gonzalez, PhD, MSc
The Future of ITP Care: Exploring New Treatments
The Future of ITP Care: Exploring New Treatments
Project Oncology®
The Future of ITP Care: Exploring New Treatments
Michele Lambert, MD, MSTR
- Michele Lambert, MD, MSTR
Diagnosing Castleman Disease: Key Considerations
Diagnosing Castleman Disease: Key Considerations
Project Oncology®
Diagnosing Castleman Disease: Key Considerations
Mateo Bustamante
- Mateo Bustamante
Revolutionizing Breast Cancer Care: The Emerging Role of Liquid Biopsy Technologies
Revolutionizing Breast Cancer Care: The Emerging Role of Liquid Biopsy Technologies
Project Oncology®
Revolutionizing Breast Cancer Care: The Emerging Role of Liquid Biopsy Technologies
Heather A. Parsons, MD, MPH
- Heather A. Parsons, MD, MPH
Improving Diagnosis of Castleman Disease: The Key Role of Stromal Cells
Improving Diagnosis of Castleman Disease: The Key Role of Stromal Cells
Project Oncology®
Improving Diagnosis of Castleman Disease: The Key Role of Stromal Cells
Joshua Brandstadter, MD, PhD, MSc
- Joshua Brandstadter, MD, PhD, MSc
Clinical evidence behind emerging targeted therapy strategies in patients with metastatic NSCLC
Clinical evidence behind emerging targeted therapy strategies in patients with metastatic NSCLC
MinuteCE®
Clinical evidence behind emerging targeted therapy strategies in patients with metastatic NSCLC
Luis Paz-Ares, MD, PhD; Helena Yu, MD
1.00 program credit
- Luis Paz-Ares, MD, PhD
- Helena Yu, MD
- Matthew Gubens, MD, MS
1.00 program credit
Incorporation of guidelines-concordant care for advanced NSCLC with second-line targeted therapies
Incorporation of guidelines-concordant care for advanced NSCLC with second-line targeted therapies
MinuteCE®
Incorporation of guidelines-concordant care for advanced NSCLC with second-line targeted therapies
Luis Paz-Ares, MD, PhD; Helena Yu, MD
1.00 program credit
- Luis Paz-Ares, MD, PhD
- Helena Yu, MD
- Matthew Gubens, MD, MS
1.00 program credit
Clinical evidence driving guidelines for immunotherapy in the neoadjuvant and adjuvant settings of NSCLC
Clinical evidence driving guidelines for immunotherapy in the neoadjuvant and adjuvant settings of NSCLC
MinuteCE®
Clinical evidence driving guidelines for immunotherapy in the neoadjuvant and adjuvant settings of NSCLC
Luis Paz-Ares, MD, PhD; Helena Yu, MD
1.00 program credit
- Luis Paz-Ares, MD, PhD
- Helena Yu, MD
- Matthew Gubens, MD, MS
1.00 program credit

36/11